{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzma8e\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzma8e\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;7\\\/3\\\/27\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;7\\\/3\\\/27\u0022}],\u0022ac\u0022:{\u0022spmdc;7\\\/3\\\/27\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;7\\\/3\\\/27\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/cdn\/css\/http\/css_Xg7z6oCTVgud_Q0huYz9x9iiD5H_2YPSJ5z2ZViSWdY.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n\u003Cp id=\u0022p-1\u0022\u003EThis article discusses a phase 3 Study of vinflunine Versus docetaxel in patients with advanced\nnon-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen, as well as\nresults from the IRIS Study, and the use of surgery alone or surgery plus induction\npaclitaxel\/carboplatin chemotherapy in early stage NSCLC.\u003C\/p\u003E\n\u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003ERespiratory Cancers\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ECancer\u003C\/li\u003E\u003C\/ul\u003E\u003Cp id=\u0022p-2\u0022\u003ESecond-line treatment in patients with non small cell lung cancer (NSCLC) is challenging because\nthe number of patients which are active is very limited, the response rate is well below 10%,\nand the prolongation of life is within weeks to months, rather than months to years. Additionally,\nthere are very few drug options for treatment in the second-line setting; the three FDA-approved\ndrugs are docetaxel, pemetrexed and erlotinib. Docetaxel has long been the standard for use in this\nsetting; pemetrexed was approved based on the surrogate endpoint of response rate, though overall\nsurvival benefits have yet to be determined. Erlotinib has been shown to produce survival benefits\nwhen used in a second-line or even third-line regimen, though additional options for these patients\nare still necessary. The main objective of this study was to confirm non-inferiority of possible new\nsecond-line therapy, vinflunine (VFL), docetaxel (DTX), with respect to progression-free survival\n(PFS).\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EPatient characteristics were well balanced between the two arms of the study and were very\ntypical for this category of patients; the majority of patients were male, the tumor extent at entry\nwas mainly metastatic and the majority of patients had more than one organ involved. All patients\nreceived platinum-based chemotherapy.\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EThe extent of toxicity is very important in second-line treatment strategies as the patients have\nalready been exposed to cytotoxic drugs. The number of cycles tolerated between the study arms was\nvery comparable: 3.5 vs 3.7 in the VFL and DTX arms, respectively.\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003ENeutropenia was the most frequent adverse event at 39%, though there was no significant\ndifference between the two study arms (\u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable\n1\u003C\/a\u003E). The only significant difference observed was in grade 3 and 4 anemia; there was a greater\nincidence of anemia associated with VFL administration. The incidence of the non-hematological\ntoxicities alopecia, nail disorders, edema, diarrhea and myalgia were significantly more in the DTX\narm. Conversely, injection site reactions, vomiting, abdominal pain and constipation were much more\nfrequent in the VFL arm. The lower incidence of vomiting in the DTX arm may be due to the\nadministration of corticosteroids for 3 days prior to chemotherapy.\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/11108\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/11108\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/11108\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1:\u003C\/span\u003E \n\u003Cp id=\u0022p-6\u0022 class=\u0022first-child\u0022\u003EHaematological Toxicity Observed in Patients Receiving VFL and DTX.\u003C\/p\u003E\n\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-7\u0022\u003EThere were no significant differences in objective response rates or in disease control between\nthe two study arms. Additionally, there were no differences in the primary objective of PFS (\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E); the median PFS was 2.3 months for\nboth agents. Almost identical overall survival rates were likewise observed.\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/7\/3\/27\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022PFS Between Patients Receiving VFL and DTX.\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-287057659\u0022 data-figure-caption=\u0022PFS Between Patients Receiving VFL and DTX.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 1:\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/7\/3\/27\/F1.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/7\/3\/27\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/7\/3\/27\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/11099\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1:\u003C\/span\u003E \n\u003Cp id=\u0022p-8\u0022 class=\u0022first-child\u0022\u003EPFS Between Patients Receiving VFL and DTX.\u003C\/p\u003E\n\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-9\u0022\u003E\u201cIn conclusion, there is no clear winner in this trial,\u201d commented Maciej\nKrzakowski, MD, Sklodowska-Curie Memorial Cancer Centre \u0026amp; Institute of Oncology, when\nreflecting on the results of this phase 3 trial.\u003C\/p\u003E\u003Cp id=\u0022p-10\u0022\u003EBoth VFL and DTX show similar efficacy in patients treated with a platinum containing regimen for\nadvanced NSCLC patients. Different toxicities were observed between the two drugs, but both were\nmanageable allowing a median relative dose intensity of 98%. Vinflunine may therefore offer a\nnew and useful alternative for second-line therapy in advanced NSCLC.\u003C\/p\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n\u003Ch2 class=\u0022\u0022\u003ESurgery Alone or Surgery Plus Induction Paclitaxel\/Carboplatin Chemotherapy in Early Stage\nNon-Small Cell Lung Cancer\u003C\/h2\u003E\n\u003Cp id=\u0022p-11\u0022\u003ENon-small cell lung cancer (NSCLC) patients with clinically staged IB-IIIA disease have very poor\n5-year survival rates. A large phase 3 trial found that preoperative paclitaxel\/carboplatin was\nfeasible and encouraged survival [Pisters K. \u003Cem\u003EJTCVS\u003C\/em\u003E 2000]. Therefore, the main\nobjective of this study was to determine if three cycles of preoperative paclitaxel\/carboplatin\nchemotherapy improves survival when compared to surgery alone in stage IB, II and IIIA NSCLC.\nAdditionally, the investigators compared operative mortality, toxicities and response rates among\nthe trial arms. It should be noted that at the time of trial design, phase 3 studies supported\npreoperative, but not adjuvant chemotherapy.\u003C\/p\u003E\n\u003Cp id=\u0022p-12\u0022\u003EThe targeted accrual number for this study was 600 patients, but accrual was stopped prematurely\ndue to developing data indicating that adjuvant chemotherapy was beneficial. Therefore, only 354\npatients were included in this trial; 18 were ineligible. Eligible patients were randomized to\nreceive either 3 cycles of paclitaxel (225mg\/m\u003Csup\u003E2\u003C\/sup\u003E as a 3 hour infusion)\/carboplatin\n(AUC=6) followed by surgical resection or surgery alone. Patient characteristics were\nbalanced between the two arms: the average age was 64\u201365 years, roughly one-third of the\npatients were female, about two-thirds of the patients had stage IB-IIA disease and squamous cell\nhistology predominated with 34% and 42% in the preoperative and surgery alone arms,\nrespectively.\u003C\/p\u003E\n\u003Cdiv id=\u0022sec-2\u0022 class=\u0022subsection\u0022\u003E\n\u003Ch3\u003EInduction Chemotherapy Results\u003C\/h3\u003E\n\u003Cp id=\u0022p-13\u0022\u003EA total of 79% of patients completed all three cycles of induction therapy; adverse events\nand refusal were the most common causes of non-compliance. Three percent (3%) of patients had\na complete response to therapy, 38% of patients had a partial response, 43% of\npatients had stable disease and 9% of patients had progressive disease; the remainder of\npatients could not be assessed. Additionally, induction chemotherapy was well tolerated; grade 3 and\n4 events were uncommon, with the exception of neutropenia which was seen in 48% of\npatients.\u003C\/p\u003E\n\u003C\/div\u003E\n\u003Cdiv id=\u0022sec-3\u0022 class=\u0022subsection\u0022\u003E\n\u003Ch3\u003ESurgery Results\u003C\/h3\u003E\n\u003Cp id=\u0022p-14\u0022\u003EComplete resection was performed in 94% of the preoperative chemotherapy group and\n89% of the surgery alone arm (p=0.10). Seven (7) out of 169 patients in the\npostoperative period in the chemotherapy arm died, while 4 out of 167 patients died in the surgery\nalone arm.\u003C\/p\u003E\n\u003C\/div\u003E\n\u003Cdiv id=\u0022sec-4\u0022 class=\u0022subsection\u0022\u003E\n\u003Ch3\u003ESurvival Results\u003C\/h3\u003E\n\u003Cp id=\u0022p-15\u0022\u003EProgression-free survival (PFS) was not statistically different between the two arms of this\ntrial at a median follow-up time of 53 months (\u003Ca id=\u0022xref-fig-2-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 1\u003C\/a\u003E), though the results tended toward statistical significance favoring preoperative\nchemotherapy (33 months vs 21 months in the preoperative and surgery alone arms, respectively;\np=0.07). The overall survival rates, however, did not show this trend.\u003C\/p\u003E\n\u003Cdiv id=\u0022F2\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/7\/3\/27\/F2.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022PFS in Patients Receiving Preoperative Chemotherapy vs Those Who Underwent Surgery Alone.\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-287057659\u0022 data-figure-caption=\u0022PFS in Patients Receiving Preoperative Chemotherapy vs Those Who Underwent Surgery Alone.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 1:\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/7\/3\/27\/F2.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/7\/3\/27\/F2.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/7\/3\/27\/F2.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/11103\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1:\u003C\/span\u003E \n\u003Cp id=\u0022p-16\u0022 class=\u0022first-child\u0022\u003EPFS in Patients Receiving Preoperative Chemotherapy vs Those Who Underwent Surgery Alone.\u003C\/p\u003E\n\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n\u003Cp id=\u0022p-17\u0022\u003EAlthough the results of this trial did not achieve statistical significance, they continue to\nsupport the role of chemotherapy in patients with operable NSCLC. The authors point out that the\nhazard ratios achieved in this study are similar to those of other trials that did reach statistical\nsignificance. Additionally, this trial was stopped early due to positive results in trials using\nadjuvant chemotherapy, thus trials comparing preoperative and postoperative chemotherapy are\nwarranted. Finally, an individual patient-based meta-analysis of induction chemotherapy is being\nconducted and will hopefully elucidate the future role of such treatment strategies.\u003C\/p\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cdiv class=\u0022section results\u0022 id=\u0022sec-5\u0022\u003E\n\u003Ch2 class=\u0022\u0022\u003EResults from the IRIS-Study\u003C\/h2\u003E\n\u003Cp id=\u0022p-18\u0022\u003ESmall cell lung cancer (SCLC) comprises approximately 15\u201320% of all lung cancers,\nand in the majority of patients, is diagnosed in the extensive disease (ED) stage and has relatively\npoor prognoses. Indeed, with currently available therapies, the median survival time is only between\n7\u201310 months. Recent studies have shown conflicting activities of irinotecan, a topoisomerase\nI inhibitor, in the treatment of SCLC [Noda K. \u003Cem\u003EN Eng J Med\u003C\/em\u003E 2000; Hanna N. \u003Cem\u003EJ\nClin Onc\u003C\/em\u003E 2006]. The purpose of this study was to determine if the superiority of irinotecan\nover etoposide, as demonstrated in the study by Noda et al, could be replicated.\u003C\/p\u003E\n\u003Cp id=\u0022p-19\u0022\u003EThe patient characteristics were well balanced between the two study arms; of note, a large\nnumber of patients were \u0026gt;70 years of age and almost 50% of patients were in\nperformance status (PS) category 2 or higher. After stratification for PS, age and institution,\npatients were randomized to receive carboplatin and either irinotecan intravenously on day 1 and\nevery 21 days thereafter (IC), or etoposide orally on days 1\u20135 and repeated every 21 days\n(EC). There were no limitations in this study of WHO PS; brain metastases were allowed, though\nunimpaired mental status was required. Patients with previous systemic cytotoxicity and other active\ncancers were, however, excluded. The primary endpoint for this study was overall survival (OS) and\nthe secondary endpoints were quality of life (QoL) and complete response rate (CR).\u003C\/p\u003E\n\u003Cp id=\u0022p-20\u0022\u003EApproximately 90% of patients received at least 2 cycles of chemotherapy, with the full 4\ncycles being administered to 80% of patients. Patients receiving IC had a significant\nsurvival advantage over those receiving EC (8.5 months vs 7.1 months, respectively; p=0.02).\nAdditionally, 18 patients receiving IC were classified as complete responders, whereas only 7\nreceiving EC were classified as such (p=0.02). There were no significant differences between\ngrade 3 and 4 toxicities for leucopenia or anemia; thrombocytopenia was significantly more common in\nthe EC group, while diarrhea was more frequent in the IC arm (\u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\n\u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/11113\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/11113\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/11113\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \n\u003Cp id=\u0022p-21\u0022 class=\u0022first-child\u0022\u003EToxicity Profile of Patients Receiving IC vs EC Treatment.\u003C\/p\u003E\n\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n\u003Cp id=\u0022p-22\u0022\u003EThe results of this study support the use of carboplatin plus irinotecan in the treatment of\nextensive disease SCLC. This drug regimen yields a significantly longer median OS and does not\ncompromise quality of life. While the median survival time was shorter than those observed in\nsimilar trials, the investigators believe this was the result of the selection of a very\nrepresentative patient population. In other words, no upper age limit or PS requirement was defined\nfor this study which likely resulted in a sicker population of patients at onset. While the\ntoxicities varied depending on the study, overall QoL was not severely different in the two study\narms. Finally, this study supports the data published by Noda et al in 2000 and adds to the growing\nbody of data defining irinotecan as a potent SCLC drug.\u003C\/p\u003E\n\u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2007 MD Conference Express\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/7\/3\/27.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_figures.js?nzma8e\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzma8e\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_tables.js?nzma8e\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}